Witam

a u dzieci z rodzinną hypercholesterolemią? Czy też dieta
Kwaśniewskiego. Włączanie statyn już małym dzieciom wydaje
mi się ryzykowne ale takie badania (podaję to dla równowagi
tych, które cytują zwolennicy diet wysokotłuszczowych)
przeprowadza się również

-------------
By Will Boggs, MD

NEW YORK (Reuters Health) Aug 07 - Statin therapy is safe and effective
for children with heterozygous familial hypercholesterolemia (HeFH),
according to findings published in the August issue of Arteriosclerosis,
Thrombosis, and Vascular Biology.

"When a child has been diagnosed with heterozygous familial
hypercholesterolemia, statin treatment should be considered for all
children older than 8 years," Dr. Barbara A. Hutten from Academic Medical
Center, Amsterdam, The Netherlands, told Reuters Health.

Dr. Hutten and colleagues performed a meta-analysis on safety outcomes of
randomized placebo-controlled trials which evaluated statin treatment in
children and adolescents with HeFH.

Compared with placebo, statin therapy reduced total cholesterol a mean 25%
and LDL cholesterol a mean 30%, the authors report.

Smaller decreases in ApoB were associated with statin therapy, as were
significant increases in HDL cholesterol and ApoA1.

Statin therapy was not associated with an increased risk of an adverse
event, the report indicates, and there were no differences in the number
of children with marked elevations in lab values between statin and
placebo groups.

Height increased slightly more in the statin group than in the placebo
group, the investigators say, but there were no significant differences
between the groups in sexual development.

"Based on our meta-analysis, we cannot draw any conclusions with respect
to a preferred statin for children," Dr. Hutten said. "The number of
studies in children is relatively low and not all types and doses of
statins have been studied in children as of yet."

"Even though the meta-analysis shows that statin treatment seems safe in
children and adolescents, long-term - or actually life-long - safety still
needs to be investigated," Dr. Hutten explained. "It is unknown whether
the risk reduction at later age differs between various types of statins
used during childhood."

"For their actual decision of starting treatment, physicians should
balance benefit and risk, based on the personal situation and the risk
profile of each individual child, which depends on family history, lipid
profile, lifestyle, etc.," Dr. Hutten said. "Also, patients' and/or
parents' preferences may play a role in the decision when to start
treatment."

"Furthermore," Dr. Hutten cautioned, "the minimal age of children in the
studies included in the meta-analyses was 8 years, and we cannot make any
recommendations for children below this age."

Arterioscler Thromb Vasc Biol 2007;27:1803-1810.

---------------------------------

P.
--
Piotr Kasztelowicz P...@a...torun.pl
http://www.am.torun.pl/~pekasz
http://www.am.torun.pl
PGP Key IDs: DH/DSS:0xF3EED8AF